S Wong1, M Appleberg, C M Ward, D R Lewis. 1. Department of Vascular Surgery, The Royal North Shore Hospital, St Leonard's, Sydney, NSW 2065, Australia.
Abstract
BACKGROUND: Aspirin is effective at reducing the cardiovascular event rate in defined patient groups. The introduction of antiplatelet therapies other than aspirin and the concept of aspirin resistance have led to critical reappraisal of current treatment. This review aims to clarify the evidence for aspirin resistance in patients with atherosclerosis. METHODS: Medline search was performed to identify publications concerned with antiplatelet effects of aspirin and failure of aspirin therapy. Manual cross referencing was also performed. RESULTS AND CONCLUSION: Wide variations in the rate of aspirin resistance (5.5-75%) have been reported. The lack of consensus on an appropriate definition and the number of different tests used to investigate aspirin resistance needs to be addressed. There are few studies where the primary aim was to document aspirin resistance or aspirin non-response. Further work should aim to investigate if aspirin resistance is clinically important and, if it is, what treatments may be beneficial to the at risk patient.
BACKGROUND:Aspirin is effective at reducing the cardiovascular event rate in defined patient groups. The introduction of antiplatelet therapies other than aspirin and the concept of aspirin resistance have led to critical reappraisal of current treatment. This review aims to clarify the evidence for aspirin resistance in patients with atherosclerosis. METHODS: Medline search was performed to identify publications concerned with antiplatelet effects of aspirin and failure of aspirin therapy. Manual cross referencing was also performed. RESULTS AND CONCLUSION: Wide variations in the rate of aspirin resistance (5.5-75%) have been reported. The lack of consensus on an appropriate definition and the number of different tests used to investigate aspirin resistance needs to be addressed. There are few studies where the primary aim was to document aspirin resistance or aspirin non-response. Further work should aim to investigate if aspirin resistance is clinically important and, if it is, what treatments may be beneficial to the at risk patient.
Authors: Laura M Bozzi; Braxton D Mitchell; Joshua P Lewis; Kathy A Ryan; William R Herzog; Jeffrey R O'Connell; Richard B Horenstein; Alan R Shuldiner; Laura M Yerges-Armstrong Journal: Curr Vasc Pharmacol Date: 2016 Impact factor: 2.719
Authors: L M Yerges-Armstrong; S Ellero-Simatos; A Georgiades; H Zhu; J P Lewis; R B Horenstein; A L Beitelshees; A Dane; T Reijmers; T Hankemeier; O Fiehn; A R Shuldiner; R Kaddurah-Daouk Journal: Clin Pharmacol Ther Date: 2013-06-11 Impact factor: 6.875
Authors: Alia Uzra Kazimi; Christian Friedrich Weber; Michael Keese; Wolfgang Miesbach Journal: Clin Appl Thromb Hemost Date: 2021 Jan-Dec Impact factor: 2.389